Galapagos, GSK Successfully Conclude Phase IIa Study of Skin Disease Drug

Belgian biotech group Galapagos NV said it has successfully concluded the Phase IIa study of a skin disease drug it is developing with Britain’s GlaxoSmithKline.
Reuters